Delivery Order SPE2DR25D1053-SPE2DR26FT680
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) under a firm fixed-price arrangement with a ceiling value of $3,676.12. This is a non-set-aside competitive award with an ultimate completion date of May 12, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is one of the nation's largest pharmaceutical distributors and serves as a critical vendor for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on November 6, 2025, for $4,027.69 to supply Ingrezza 80 mg capsules (30-count units). This is a firm fixed-price contract with a completion date of December 1, 2025, and no set-aside designation was used. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) with a ceiling value of $3,676.12. This is a firm fixed-price delivery order with an ultimate completion date of October 7, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (quantity: 30 units) with a ceiling value of $14,704.48. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) with a ceiling value of $7,748.14. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The order is scheduled for completion by November 25, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3,676.12. This is a firm fixed-price delivery order with an ultimate completion date of October 20, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count package), with an ultimate completion date of September 24, 2025. This firm fixed price delivery order, awarded on September 3, 2025, represents a non-competitive set-aside contract and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency awarded a $4,027.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ingrezza 80 mg capsules (30-count units). This is a non-set-aside, competitively awarded contract with an ultimate completion date of May 15, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,027.70 to supply Ingrezza 80 mg capsules (30-count packaging) with a firm fixed price structure. The award, issued on August 5, 2025, is scheduled for completion by August 26, 2025, and represents a non-set-aside, competitively awarded contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a child...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, for the supply of Ingrezza 60 mg capsules (30-count unit). The contract, valued at $4,049.61 with a firm fixed price structure, was awarded on August 4, 2025, with an ultimate completion date of August 25, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's capability to meet federal procurement requirements in open competition....
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT680Delivery Order
The Defense Logistics Agency awarded a competitively competed delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ingrezza 40 mg capsules (30-count packages) valued at $11,622.18, with completion required by December 1, 2025. This firm fixed price delivery order represents a non-set-aside award and will be fulfilled from the vendor's corporate office located in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a substantial federal contracting portfolio with the Defense Logistics Agency focused on delivering pharmaceuticals and medical supplies to military and veteran healthcare systems. Ingrezza is an FDA-approved antipsychotic medication used in the treatment of tardive dyskinesia, reflecting the company's role in supplying specialized neurological medications to support Defense Health Agency and other federal healthcare customers. The company's demonstrated capability to compete successfully for pharmaceutical procurement across multiple therapeutic domains positions it as a critical vendor within the federal medical supply chain supporting military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 11/6/25 |